FBRX · Forte Biosciences, Inc.
$76.56
-0.09 (-0.12%)
At close · Jul 29
Market Cap
$1.06B
Shares
13.89M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$76.65
Open$76.50
Day$76.50–76.68
52W$9.10–76.68
Avg vol 30d1.4M
Short int2.1M · 14.8% float · 1.7d
Short vol28%
Last earningsMay 10, 2021
DataJan 2020–Jul 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+203%
above
Price vs 50-day avg
+175%
above
RSI (14)
92
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+264%
trailing
6-month return
+122%
trailing
YTD return
+181%
this year
Relative strength
+115%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $28 › 200d $25 — 50d above 200d
Institutional flow
Accumulating
4 of 69 funds reported for Jun 30 · net +13.8K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.84% of float · ▲ +8.9% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
69 holders — near 1-yr high, broad support
Squeeze score
90
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+61%
Y/Y
Free cash flow
$-51.0M
Balance sheet
$50.8M
net cash
Quant / Vol
risk profile
Volatility
128%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+203%
Bullish
Price vs 50-day avg
+175%
Bullish
RSI (14)
92
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
Golden cross
50d $28 › 200d $25 — 50d above 200d
Institutional flow
Accumulating
4 of 69 funds reported for Jun 30 · net +13.8K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.84% of float · ▲ +8.9% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
69 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $9
Now $77 · 100%
52-wk high $77
vs 200-day avg +203%
vs 50-day avg +175%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FBRX
this stock
Forte Biosciences, Inc.
|
$1.06B | +181.1% | -99.8% | — | 14.8% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FBRX | +61.4% | +264.5% | +122.2% | +260.7% | +181.1% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +62.4% | +264.5% | +114.8% | +261.5% | +172.4% |